![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZMYM3 |
Gene summary for ZMYM3 |
![]() |
Gene information | Species | Human | Gene symbol | ZMYM3 | Gene ID | 9203 |
Gene name | zinc finger MYM-type containing 3 | |
Gene Alias | DXS6673E | |
Cytomap | Xq13.1 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q14202 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9203 | ZMYM3 | HCC1_Meng | Human | Liver | HCC | 1.62e-33 | 6.66e-02 | 0.0246 |
9203 | ZMYM3 | HCC2_Meng | Human | Liver | HCC | 1.70e-05 | 5.19e-02 | 0.0107 |
9203 | ZMYM3 | HCC1 | Human | Liver | HCC | 2.31e-02 | 3.13e+00 | 0.5336 |
9203 | ZMYM3 | HCC2 | Human | Liver | HCC | 8.33e-06 | 2.89e+00 | 0.5341 |
9203 | ZMYM3 | S014 | Human | Liver | HCC | 2.52e-07 | 4.06e-01 | 0.2254 |
9203 | ZMYM3 | S015 | Human | Liver | HCC | 2.33e-08 | 5.28e-01 | 0.2375 |
9203 | ZMYM3 | S016 | Human | Liver | HCC | 1.47e-06 | 3.73e-01 | 0.2243 |
9203 | ZMYM3 | S028 | Human | Liver | HCC | 7.75e-11 | 4.70e-01 | 0.2503 |
9203 | ZMYM3 | S029 | Human | Liver | HCC | 2.56e-03 | 3.30e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | ![]() |
Oral cavity | LP | ![]() |
Oral cavity | EOLP | ![]() |
Oral cavity | NEOLP | ![]() |
Esophagus | HGIN | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002260422 | Liver | HCC | regulation of cell morphogenesis | 188/7958 | 309/18723 | 4.84e-11 | 1.82e-09 | 188 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZMYM3 | SNV | Missense_Mutation | c.3634N>G | p.Leu1212Val | p.L1212V | Q14202 | protein_coding | deleterious(0.02) | possibly_damaging(0.836) | TCGA-A1-A0SP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | ||
ZMYM3 | SNV | Missense_Mutation | novel | c.2214N>C | p.Gln738His | p.Q738H | Q14202 | protein_coding | deleterious(0.02) | benign(0.003) | TCGA-A7-A4SF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
ZMYM3 | SNV | Missense_Mutation | rs748625716 | c.1172C>T | p.Ala391Val | p.A391V | Q14202 | protein_coding | tolerated(0.69) | possibly_damaging(0.593) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZMYM3 | SNV | Missense_Mutation | c.426N>T | p.Glu142Asp | p.E142D | Q14202 | protein_coding | tolerated_low_confidence(0.17) | benign(0) | TCGA-B6-A0RS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
ZMYM3 | SNV | Missense_Mutation | rs775842123 | c.3761N>C | p.Ser1254Thr | p.S1254T | Q14202 | protein_coding | tolerated(0.58) | benign(0.006) | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZMYM3 | SNV | Missense_Mutation | c.275N>T | p.Pro92Leu | p.P92L | Q14202 | protein_coding | tolerated_low_confidence(0.31) | benign(0.027) | TCGA-C8-A12Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
ZMYM3 | SNV | Missense_Mutation | c.3908N>G | p.Tyr1303Cys | p.Y1303C | Q14202 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D8-A141-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
ZMYM3 | SNV | Missense_Mutation | c.3846N>G | p.Ile1282Met | p.I1282M | Q14202 | protein_coding | tolerated(0.22) | benign(0.012) | TCGA-E2-A1B5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
ZMYM3 | SNV | Missense_Mutation | c.1239N>C | p.Gln413His | p.Q413H | Q14202 | protein_coding | tolerated(0.66) | benign(0.006) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
ZMYM3 | SNV | Missense_Mutation | novel | c.3999N>T | p.Trp1333Cys | p.W1333C | Q14202 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-LL-A7T0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |